LY6K and esophageal cancer: However, compared with the results of the phase 2 esophageal cancer study using three peptides (URLC10, CDCA1, and KOC1), despite the similar CTL induction rates for URLC10 (93.3% [125/134] in the phase 3 study and 87.9% [29/33] in the phase 2 study), induction rates of CDCA1 and KOC1 in the current study were lower than those in the phase 2 study (53.7% [72/134] in the phase 3 study and 90.9% [30/33] in the phase 2 study for CDCA1; 29.9% [40/134] in the phase 3 study and 54.5% [18/33] in the phase 2 study for KOC1) [10].